Cluenex
Log inStart free
All stocks · Real Estate · Health Care REITs

Ventas VTR

Ventas scores average on business quality (5.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$82.04Oct 9, 2026
Business qualityAverage
Next earningsOct 27, 2026
Insiders, 90 daysQuiet

Why it matters

  1. What Ventas does

    Ventas owns and operates healthcare real estate, collecting rent from senior housing operators, hospitals, and medical office tenants. The business captures cash flows from an aging demographic via its massive portfolio of senior housing communities.

  2. What it does best

    Ventas excels at scaling senior housing real estate, putting up a revenue growth rate of 18.5% that places it in the top decile of its sector at the 96th percentile. This growth outpaces peer DOC at 4.6%, driven by deep senior housing operating relationships that are hard to replicate quickly.

  3. The main risk

    An interest coverage ratio of 1.6x leaves little margin for error if debt costs remain elevated or operating cash flows dip. With total debt sitting at $13.0 billion against $741 million in cash, refinancing pressures could squeeze net income if property yields stall.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin sits at 15.5% with a free cash flow margin of 65% relative to cash flow components, supported by scale. Profitability remains constrained by heavy interest expenses relative to operating income.

MoatWeak

The moat relies on specialized healthcare real estate scale, placing its ROE in the top decile at the 99th percentile. Specialized operating setups make tenant switching costly within 1-2 years.

GrowthFast

Revenue growth hit 18.5%, accelerating significantly from historical levels where revenue grew steadily from $3.8B in 2020 to $5.8B in 2025, driven by surging senior housing demand.

Financial healthWeak

Debt-to-equity of 1.0x and interest coverage of 1.6x create a heavy interest burden. Free cash flow reached $1.1B, showing improvement, but the balance sheet remains soft due to $12.3B in net debt.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on VTR

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is VTR a good business?

Ventas scores average on the Cluenex quality check (5.5 of 10), measured against its own industry. Profitability is fair, moat weak, growth fast and financial health weak.

Are insiders buying VTR?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does VTR report earnings?

Oct 27, 2026.

For members

See VTR today

  • Today's verdict on VTR, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Ventas (VTR)”, https://cluenex.com/stocks/vtr/, data as of Oct 10, 2026.